logo

Biomarin Pharmaceutical Inc. (BMRN)



Trade BMRN now with
  Date
  Headline
1/8/2023 11:26:44 AM BioMarin Pharma Announces Positive Results From Phase 3 GENEr8-1 Study Of ROCTAVIAN For Adults With Severe Hemophilia A
11/23/2022 8:30:59 AM BioMarin Announces Advancements In FDA Review Of ROCTAVIAN For Adults With Severe Hemophilia A
10/26/2022 4:14:50 PM BioMarin Q3 Loss/share $0.04 Vs. Loss $0.20 Year Ago
9/15/2022 8:35:45 AM BioMarin's Gene Therapy For Adults With Severe Hemophilia A, ROCTAVIAN, Assessed To Provide Cost Savings
9/13/2022 9:47:55 AM Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Neutral With $74 Price Target
8/4/2022 1:09:50 PM Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) FY23 Rev. Estimate To 2327 M From 2319 M
8/4/2022 1:09:38 PM Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q4 23 Rev. Estimate To 587.0 M From 585.0 M
8/4/2022 1:09:22 PM Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q3 23 Rev. Estimate To 583.6 M From 581.7 M
8/4/2022 1:09:06 PM Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q2 23 Rev. Estimate To 580.3 M From 578.4 M
8/4/2022 1:08:51 PM Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q1 23 Rev. Estimate To 576.6 M From 574.8 M
8/4/2022 1:08:36 PM Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) FY22 Rev. Estimate To 2100 M From 2084 M
8/4/2022 1:08:23 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q4 22 Rev. Estimate To 527.3 M From 531.6 M
8/4/2022 1:08:07 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q3 22 Rev. Estimate To 520.5 M From 521.7 M
8/4/2022 1:07:42 PM Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) FY23 Estimate To 0.54 From 0.42